MUC1 and COVID-19: An additional systematic review and meta-analysis (Naderi and Rahimzadeh, 2022) also showed that serum levels of KL-6 were higher in severe COVID19 patients as compared to nonsevere and healthy subjects, suggesting the use of KL-6 as a potential biomarker for predicting severity of COVID19.